Metavention said today that it closed a $65 million Series C round with funding from New Enterprise Associates, Sanderling Ventures and others.
The medical device maker plans to use the funds to optimize its transcatheter-based metabolic neuromodulation therapy for people with Type II diabetes and prepare it for a Phase II trial in the U.S.
Get the full story at our sister site, Drug Delivery Business News.